# BOLERO-2 (NCT00863655)

> Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00863655
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Breast Cancer
- Interventions: Everolimus; Exemestane; Everolimus Placebo
- Enrollment: 724
- Primary outcome: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments.

## Commentary we found

- Podcasts: 23
- YouTube: 16
- X threads: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=bolero-2-nct00863655

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00863655", "email": "<work email>"}; the inbox owner confirms by the emailed link.